Explainable Machine Learning to Predict Treatment Response in Advanced Non–Small Cell Lung Cancer
JCO Clinical Cancer Informatics · 2025-01 · (9)
DOI: 10.1200/cci-24-00157 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2025-01. Verfasst von Vinayak S Ahluwalia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Machine Learning, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Immune checkpoint inhibitors (ICIs) have demonstrated promise in the treatment of various cancers. Single-drug ICI therapy (immuno-oncology [IO] monotherapy) that targets PD-L1 is the standard of care in patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression ≥50%. We sought to find out if a machine learning (ML) algorithm can perform better as a predictive biomarker than PD-L1 alone. METHODS Using a real-world, nationwide electronic health record–derived deidentified database of 38,048 patients with advanced NSCLC, we trained binary prediction algorithms to predict likelihood of 12-month progression-free survival (PFS; 12-month PFS) and 12-month overall survival (OS; 12-month OS) from initiation of first-line therapy. We evaluated the algorithms by calculating the AUC on the test set. We plotted Kaplan-Meier curves and fit Cox survival models comparing survival between patients who were classified as low-risk (LR) for 12-month disease progression or 12-month mortality versus those classified as high-risk. RESULTS The ML algorithms achieved an AUC of 0.701 (95% CI, 0.689 to 0.714) and 0.718 (95% CI, 0.707 to 0.730) for 12-month PFS and 12-month OS, respectively. Patients in the LR group had lower 12-month disease progression (hazard ratio [HR], 0.47 [95% CI, 0.45 to 0.50]; P < .001) and 12-month all-cause mortality (HR, 0.31 [95% CI, 0.29 to 0.34]; P < .0001) compared with the high-risk group. Patients deemed LR for disease progression and mortality on IO monotherapy were less likely to progress (HR, 0.53 [95% CI, 0.46 to 0.61]; P < .0001) or die (HR, 0.30 [95% CI, 0.24 to 0.37]; P < .001) compared with the high-risk group. CONCLUSION An ML algorithm can more accurately predict response to first-line therapy, including IO monotherapy, in patients with advanced NSCLC, compared with PD-L1 alone. ML may better aid clinical decision making in oncology than a single biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
- Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA.
- Emory University School of Medicine, Atlanta, GA.
- Emory Winship Cancer Institute, Atlanta, GA.
ORCID-Profile: Vinayak S Ahluwalia, Ravi B Parikh
Förderung
- NCI NIH HHS
Zitieren
APA
Ahluwalia, V. S., & Parikh, R. B. (2025). Explainable Machine Learning to Predict Treatment Response in Advanced Non–Small Cell Lung Cancer. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci-24-00157
Vancouver
Ahluwalia VS, Parikh RB. Explainable Machine Learning to Predict Treatment Response in Advanced Non–Small Cell Lung Cancer. JCO Clinical Cancer Informatics. 2025. doi:10.1200/cci-24-00157
BibTeX
@article{Ahluwalia2025,
author = {Ahluwalia, Vinayak S and Parikh, Ravi B},
title = {Explainable Machine Learning to Predict Treatment Response in Advanced Non–Small Cell Lung Cancer},
journal = {JCO Clinical Cancer Informatics},
year = {2025},
number = {9},
doi = {10.1200/cci-24-00157}
}
EUVIMED